Advisor Group Holdings, Inc. Provention Bio, Inc. Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$6.7 - $24.21 $109,256 - $394,792	-16,307 Reduced 76.38%	5,042 $121,000
Q4 2022 Feb 10, 2023	SELL	$4.52 - $10.57 $386,853 - $904,654	-85,587 Reduced 80.04%	21,349 $225,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $50,935 - $83,457	14,850 Added 16.13%	106,936 $481,000
Q2 2022 Aug 10, 2022	BUY	$3.65 - $7.3 $56,903 - $113,807	15,590 Added 20.38%	92,086 $369,000
Q1 2022 May 04, 2022	BUY	$3.4 - $7.88 $25,738 - $59,651	7,570 Added 10.98%	76,496 $560,000
Q3 2021 Nov 05, 2021	BUY	$5.66 - $8.33 $11,370 - $16,734	2,009 Added 3.0%	68,926 $441,000
Q2 2021 Aug 02, 2021	BUY	$6.71 - $11.04 $104,239 - $171,506	15,535 Added 30.23%	66,917 $564,000
Q1 2021 May 13, 2021	SELL	$10.12 - $19.45 $12,295 - $23,631	-1,215 Reduced 2.31%	51,382 $540,000
Q4 2020 Feb 10, 2021	BUY	$11.79 - $18.94 $5,388 - $8,655	457 Added 0.88%	52,597 $890,000
Q3 2020 Nov 12, 2020	BUY	$10.34 - $15.2 $364,205 - $535,389	35,223 Added 208.21%	52,140 $669,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $38,011 - $82,739	4,867 Added 40.39%	16,917 $238,000
Q1 2020 May 18, 2020	BUY	$5.42 - $17.75 $65,311 - $213,887	12,050 New	12,050 $111,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.